Differential molecular information of maurotoxin peptide recognizing IKCaand Kv1.2 channels explored by computational simulation

BMC Structural Biology

Volumn 11, Issue , 2011, Pages

  Yi, Hong ^a   Qiu, Su ^a   Wu, Yingliang ^a   Li, Wenxin ^a   Wang, Baoshan ^a  

^a WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM ACTIVATED POTASSIUM CHANNEL; LYSINE; MAUROTOXIN INHIBITORY PEPTIDE; PEPTIDE; POTASSIUM CHANNEL KV1.2; SCORPION VENOM; TYROSINE; UNCLASSIFIED DRUG; INTERMEDIATE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; KCNN4 PROTEIN, HUMAN; MAUROTOXIN; VOLTAGE GATED POTASSIUM CHANNEL;

ARTICLE; BETA SHEET; COMPLEX FORMATION; MOLECULAR BIOLOGY; POROSITY; PROTEIN BINDING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; STATIC ELECTRICITY; CHEMICAL STRUCTURE; CHEMISTRY; COMPUTER SIMULATION; METABOLISM; PROTEIN SECONDARY STRUCTURE;

SCORPIONES;

COMPUTER SIMULATION; INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; KV1.2 POTASSIUM CHANNEL; MODELS, MOLECULAR; POTASSIUM CHANNELS, CALCIUM-ACTIVATED; POTASSIUM CHANNELS, VOLTAGE-GATED; PROTEIN BINDING; PROTEIN STRUCTURE, SECONDARY; SCORPION VENOMS;

EID: 78951473617     PISSN: None     EISSN: 14726807     Source Type: Journal    
DOI: 10.1186/1472-6807-11-3     Document Type: Article

References (40)

1. Three-dimensional structure of scorpion toxins: Towards a new model of interaction with potassium channels. H Darbon E Blanc JM Sabatier, Perspect Drug Discov (Pubitemid 29304032)
2. +- channels. LD Possani B Selisko GB Gurrola, Perspect Drug Discovery Des 1999 16 15 40 10.1023/A:1017062613503 (Pubitemid 29304031)
3. Peptides and genes coding for scorpion toxins that affect ion-channels. LD Possani E Merino M Corona F Bolivar B Becerril, Biochimie 2000 82 861 868 10.1016/S0300-9084(00)01167-6 11086216
4. + channels and scorpion toxins. RC Rodriguez de la Vega E Merino B Becerril LD Possani, Trends Pharmacol Sci 2003 24 222 227 12767720 (Pubitemid 36588869)
5. Molecular basis of alpha-KTx specificity. KM Giangiacomo Y Ceralde TJ Mullmann, Toxicon 2004 43 877 886 10.1016/j.toxicon.2003.11.029 15208020
6. + channel pore through mutant cycles with a peptide inhibitor. P Hidalgo R MacKinnon, Science 1995 268 307 310 10.1126/science.7716527 7716527
7. Structural conservation in prokaryotic and eukaryotic potassium channels. R MacKinnon SL Cohen A Kuo A Lee BT Chait, Science 1998 280 106 109 10.1126/science.280.5360.106 9525854 (Pubitemid 28169092)
8. + channel. V Ruta Y Jiang A Lee J Chen R MacKinnon, Nature 2003 422 180 185 10.1038/nature01473 12629550 (Pubitemid 36362752)
9. Peptide leads new class of chronic pain drugs. K Garber, Nat Biotechnol 2005 23 399 10.1038/nbt0405-399 15815650 (Pubitemid 41724906)
10. Therapeutic potential of venom peptides. RJ Lewis ML Garcia, Nat Rev Drug Discov 2003 2 790 802 10.1038/nrd1197 14526382 (Pubitemid 37361811)
11. + channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. H Wulff HG Knaus M Pennington KG Chandy, J Immunol 2004 173 776 786 15240664 (Pubitemid 38924252)
12. International Union of Pharmacology. LII. Nomenclature and molecular relationships of calcium-activated potassium channels. AD Wei GA Gutman R Aldrich KG Chandy S Grissmer H Wulff, Pharmacol Rev 2005 57 463 472 10.1124/pr.57.4.9 16382103 (Pubitemid 43036436)
13. Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. H Wulff A Kolski-Andreaco A Sankaranarayanan JM Sabatier V Shakkottai, Curr Med Chem 2007 14 1437 1457 10.2174/092986707780831186 17584055 (Pubitemid 46902225)
14. + channel, IKCa1: a potential immunosuppressant. H Wulff MJ Miller W Hansel S Grissmer MD Cahalan KG Chandy, Proc Natl Acad Sci USA 2000 97 8151 8156 10.1073/pnas.97.14.8151 10884437 (Pubitemid 30460788)
15. + channel modulators for the treatment of neurological disorders and autoimmune diseases. H Wulff BS Zhorov, Chem Rev 2008 108 1744 1773 10.1021/cr078234p 18476673 (Pubitemid 351796408)
16. International Union of Pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. GA Gutman KG Chandy S Grissmer M Lazdunski D McKinnon LA Pardo GA Robertson B Rudy MC Sanguinetti W Stuhmer X Wang, Pharmacol Rev 2005 57 473 508 10.1124/pr.57.4.10 16382104 (Pubitemid 43036437)
17. 2+-activated potassium channels. NA Castle DO London C Creech Z Fajloun JW Stocker JM Sabatier, Mol Pharmacol 2003 63 409 418 10.1124/mol.63.2.409 12527813 (Pubitemid 36158377)
18. Mapping of maurotoxin binding sites on hKv1.2, hKv1.3, and hIKCa1 channels. V Visan Z Fajloun JM Sabatier S Grissmer, Mol Pharmacol 2004 66 1103 1112 10.1124/mol.104.002774 15286210 (Pubitemid 39411051)
19. + channels. R Kharrat K Mabrouk M Crest H Darbon R Oughideni MF Martin-Eauclaire G Jacquet M el Ayeb J Van Rietschoten H Rochat JM Sabatier, Eur J Biochem 1996 242 491 498 10.1111/j.1432-1033.1996.0491r.x 9022673 (Pubitemid 27121128)
20. Maurotoxin, a four disulfide bridge toxin from Scorpio maurus venom: purification, structure and action on potassium channels. R Kharrat P Mansuelle F Sampieri M Crest R Oughideni J Van Rietschoten MF Martin-Eauclaire H Rochat M El Ayeb, FEBS Lett 1997 406 284 290 10.1016/S0014-5793(97)00285-8 9136903 (Pubitemid 27166312)
21. Mechanisms of maurotoxin action on Shaker potassium channels. V Avdonin B Nolan JM Sabatier M De Waard T Hoshi, Biophys J 2000 79 776 787 10.1016/S0006-3495(00)76335-1 10920011 (Pubitemid 30626173)
22. Molecular basis of inhibitory peptide maurotoxin recognizing Kv1.2 channel explored by ZDOCK and molecular dynamic simulations. H Yi S Qiu Z Cao Y Wu W Li, Proteins 2008 70 844 854 10.1002/prot.21706 17729277 (Pubitemid 351161943)
23. Simulation of the interaction between ScyTx and small conductance calcium-activated potassium channel by docking and MM-PBSA. Y Wu Z Cao H Yi D Jiang X Mao H Liu W Li, Biophys J 2004 87 105 112 10.1529/biophysj.103.039156 15240449 (Pubitemid 38880069)
24. + channel with its specific BeKm-1 peptide: insights into the selectivity of molecular recognition. H Yi Z Cao S Yin C Dai Y Wu W Li, J Proteome Res 2007 6 611 620 10.1021/pr060368g 17269718 (Pubitemid 46340165)
25. Molecular Information of charybdotoxin blockade in the large conductance calcium-activated potassium channel. S Qiu H Yi H Liu Z Cao Y Wu W Li, J Chem Inf Model 2009 49 1831 1838 10.1021/ci900025n 19499912
26. Block of maurotoxin and charybdotoxin on human intermediate-conductance calcium-activated potassium channels (hIKCa1). V Visan JM Sabatier S Grissmer, Toxicon 2004 43 973 980 10.1016/j.toxicon.2003.12.011 15208030 (Pubitemid 38781032)
27. Evidence for domain-specific recognition of SK and Kv channels by MTX and HsTx1 scorpion toxins. I Regaya C Beeton G Ferrat N Andreotti H Darbon M De Waard JM Sabatier, J Biol Chem 2004 279 55690 55696 10.1074/jbc.M410055200 15498765 (Pubitemid 40066574)
28. The Protein Data Bank. HM Berman J Westbrook Z Feng G Gilliland TN Bhat H Weissig IN Shindyalov PE Bourne, Nucleic Acids Res 2000 28 235 242 10.1093/nar/28.1.235 10592235 (Pubitemid 30047768)
29. ZDOCK: an initial-stage protein-docking algorithm. R Chen L Li Z Weng, Proteins 2003 52 80 87 10.1002/prot.10389 12784371 (Pubitemid 36648854)
30. DA Case TA Darden TEI Cheatham CL Simmerling J Wang RE Duke R Luo KM Merz B Wang DA Pearlman, et al. Amber 8 San Francisco: University of California 2004
31. Molecular Dynamics Simulations of Nucleic Acids with a Generalized Born solvation model. TA Darden DA Case, J Am Chem Soc 2000 122 2489 2498 10.1021/ja9939385 (Pubitemid 30211961)
32. Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease. S Han H Yi SJ Yin ZY Chen H Liu ZJ Cao YL Wu WX Li, J Biol Chem 2008 283 27 19058 65 10.1074/jbc.M802054200 18480054
33. Different residues in channel turret determining the selectivity of ADWX-1 inhibitor peptide between Kv1.1 and Kv1.3 channels. SJ Yin L Jiang H Yi S Han DW Yang ML Liu H Liu ZJ Cao YL Wu WX Li, J Proteome Res 2008 7 4890 4897 10.1021/pr800494a 18937510
34. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? JM Wang P Cieplak PA Kollman, J Comput Chem 2000 21 1049 1074 10.1002/1096- 987X(200009)21:12<1049::AID-JCC3>3.0.CO;2-F
35. + channel revealed by the NMR-derived structures of scorpion toxins. J Aiyar JM Withka JP Rizzi DH Singleton GC Andrews W Lin J Boyd DC Hanson M Simon B Dethlefs, et al. Neuron 1995 15 1169 1181 10.1016/0896-6273(95)90104-3 7576659
36. Agitoxin footprinting the shaker potassium channel pore. A Gross R MacKinnon, Neuron 1996 16 399 406 10.1016/S0896-6273(00)80057-4 8789954 (Pubitemid 26072372)
37. Toxin-induced conformational changes in a potassium channel revealed by solid-state NMR. A Lange K Giller S Hornig MF Martin-Eauclaire O Pongs S Becker M Baldus, Nature 2006 440 959 962 10.1038/nature04649 16612389
38. Brownian dynamics simulations of interaction between scorpion toxin Lq2 and potassium ion channel. M Cui JH Shen JM Briggs XM Luo XJ Tan HL Jiang KX Chen RY Ji, Biophys J 2001 80 1659 1669 10.1016/S0006-3495(01)76138-3 11259281 (Pubitemid 32280983)
39. Brownian dynamics simulations of the recognition of the scorpion toxin P05 with the small-conductance calcium-activated potassium channels. M Cui JH Shen JM Briggs W Fu JL Wu YM Zhang XM Luo ZW Chi RY Ji HL Jiang KX Chen, J Mol Bio 2002 318 417 428 10.1016/S0022-2836(02)00095-5 (Pubitemid 34734836)
40. + channel: a computational approach based on experimental distance restraints extracted from thermodynamic mutant cycles. MA Eriksson B Roux, Biophys J 2002 83 2595 2609 10.1016/S0006-3495(02)75270-3 12414693 (Pubitemid 35265753)